Share Page:

Volume 22 , Issue 2
Spring 2008

Efficacy of Moclobemide in Burning Mouth Syndrome: A Nonrandomized, Open-Label Study

Filiz Namdar Pekiner, DDS, PhD/Birsay Gumru, DDS, PhD/Semih Ozbayrak, DDS, PhD

PMID: 18548844

Aims: To compare burning mouth syndrome (BMS) patients with age- and gender-matched controls for psychologic conditions, to analyze the effect of menstrual state on the intensity of burning, and to assess the efficacy of an antidepressant medication on the burning pain and psychologic status. Methods: Ninety-four patients with BMS and 94 matched control subjects participated in the study. Anxiety and depression were analyzed by means of the Spielberger State-Trait Anxiety Inventory and Zung Self-Rating Depression Scale, and the severity of the burning sensation was measured by means of a visual analog scale (VAS). In female BMS patients and controls, the menstrual state was noted (menstruating, menopausal, or postmenopausal). BMS patients were treated with the antidepressant moclobemide (150 mg 2 times daily) for 3 months. Thereafter, anxiety, depression, and burning pain intensity were reassessed. Patient-perceived satisfactory improvement for burning sensation was assessed using a 5-point categorical rating of change scale. Results: BMS patients had significantly higher anxiety and depression scores than controls (P < .05). After treatment, anxiety and depression scores as well as the VAS values for burning pain decreased significantly (P< .001). Thirty-seven patients reported good to very good improvement, and 44 reported satisfactory improvement. No adverse reactions were reported. Conclusions: The study confirmed earlier reports that BMS patients have higher anxiety and depression levels than controls. An antidepressant medication may be effective in alleviating the burning pain, at least in the short term. J Orofac Pain 2008; 22:146152

Key words: anxiety, burning mouth syndrome, depression, moclobemide, pain measurement, treatment

Full Text PDF File | Order Article


Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.


© 2021 Quintessence Publishing Co, Inc

Current Issue
Ahead of Print
Author Guidelines
Submission Form
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us